What Stryker's Apple Vision Pro Surgery Actually Is — And Why It Doesn't Change the Valuation

Stryker completed the first FDA-authorized surgery using an Apple Vision Pro headset. A hip arthroscopy at Duke Health on September 1. The application is called SportSuite Vision. It puts arthroscopic video, pre-operative CT scans, and Stryker's HipCheck and HipMap analysis software into one floating, heads-up display the surgeon wears on their face.

The press release calls it "a new chapter in digital surgery." The stock did not move. Stryker shares are down 17% over the past year and trade at 40 times next year's earnings — more than double the valuation of Medtronic, half the dividend yield, and at a premium to almost every peer in medical devices.

That disconnect is the starting point. Why is a company with this valuation profile announcing a headset integration like it is the future? And more importantly, does it change the math for the business?

The answer turns out to be almost nothing. But getting there requires understanding what this product actually is — and what Stryker is trying to sell.

The problem SportSuite Vision addresses is real. In a standard operating room, the surgeon performs arthroscopic surgery while looking at monitors positioned beside or above the surgical table. These monitors show the camera feed from inside the joint, along with pre-operative imaging and procedural data. The surgeon has to shift their gaze away from the surgical field to check measurements or scan overlays. It is an ergonomic friction point, not a clinical failure.

Stryker has been building tools for this procedure for years. HipCheck and HipMap, launched in 2019, use CT scans to create patient-specific 3D models of the hip joint, identifying deformities and planning precise corrections. These tools already work on conventional monitors. SportSuite Vision does not add new clinical capability. It moves the same information from a wall-mounted screen to a headset.

The FDA authorized this on July 17, granting a De Novo classification — the pathway for devices that are substantially equivalent to nothing already on the market. SportSuite Vision is the first application authorized by the FDA for intraoperative use with the Apple Vision Pro. That "first" matters for regulatory positioning but not for the economics.

Here is the constraint no one in the press release mentions. An Apple Vision Pro headset now costs at least $3,700, after Apple raised prices in June. A hospital needs multiple headsets — one per surgeon who wants to use it — plus cleaning, maintenance, and integration into hospital IT systems. The Vision Pro itself is still marketed as a consumer device, not a medical device, and lacks the ISO compliance that standard operating room equipment requires. Stryker's software has the FDA clearance; the hardware does not.

Meanwhile, competing approaches exist. University researchers at Pitt and UPMC are developing their own Vision Pro surgical platform, SymphonyMR, still in a pre-commercial phase. Other hospitals are experimenting with mixed-reality headsets from different vendors. The space is not settled, and Apple is not the inevitable platform.

This matters because it tells you something about Stryker's strategy. They are not selling headsets. They are using a headset to lock surgeons into their software ecosystem. HipCheck and HipMap are already installed in hospitals that do hip arthroscopy. SportSuite Vision makes that software harder to walk away from by embedding it into the surgeon's daily visual workflow. If the surgeon starts depending on having HipCheck data floating in front of them during every procedure, switching to a competitor's instrumentation becomes more friction.

That is a real business instinct. It is also a small one.

Stryker's Orthopaedics segment — which includes Sports Medicine — generated $9.5 billion in 2025, or 38% of a $25.1 billion total. Hip arthroscopy is a fraction of orthopedics, which is itself dominated by hip and knee replacements. The number of hip arthroscopy procedures in the U.S. is measured in the low hundreds of thousands annually. Even if every one of those procedures eventually used SportSuite Vision, the software revenue from this specific product line is not going to be material to a company pulling in $6.5 billion per quarter.

And adoption is slow. A recent UC San Diego study found that surgeons using the Vision Pro completed certain eye procedures 19% faster than those using conventional monitors. But that was 16 procedures in a research setting. The academic medical center where Stryker performed the first live case — Duke Health — is precisely the kind of institution that tries new things. Widespread hospital procurement is a much higher bar.

So what does this announcement actually tell you about Stryker? It tells you the company has deep regulatory execution capability. Getting a De Novo authorization for a novel device class takes time and resources, and Stryker did it in partnership with Apple, which signals relationships. It tells you Stryker is thinking about software as a retention tool, not just as a feature. And it tells you the company is comfortable spending on experimentation that may or may not produce revenue.

None of that changes the valuation question.

Stryker trades at $124 billion in market value. Forward earnings of roughly $8 per share put the stock at 40 times what analysts expect the company to earn next year. Compare that to Medtronic at 22 times, Abbott at 35 times, and Zimmer Biomet at 24 times. Stryker is the most expensive of the major medical device companies by a wide margin.

The market is pricing in sustained double-digit growth, margin expansion, and successful integration of roughly $5 billion in acquisitions completed in 2025 alone — Inari Medical for vascular, Guard Medical for wound therapy, Advanced Medical Balloons for incontinence. The company delivered $4.7 billion in free cash flow over the trailing twelve months, with a 10.7% return on invested capital. These are solid numbers for a well-run company. They do not, on their own, justify a valuation that assumes the growth will not slow.

The Apple Vision Pro announcement is not a valuation event. It is a signal about direction, not magnitude. Stryker is betting that surgeons will eventually prefer their data in a headset, and that preference will deepen the company's software moat. That bet is worth placing. It is not worth paying 40 times earnings for.

The real question for investors is not whether Stryker is shipping innovative products. It is whether the premium the market charges for Stryker reflects a durable competitive advantage or just a run of good quarters. SportSuite Vision does not answer that question. But it does show you a company that is trying to convert product relationships into workflow dependencies — which is exactly what a premium company should be doing. Whether those dependencies are worth the premium is a different conversation, and one that requires looking at cash flow growth, acquisition integration, and margin trends over the next few quarters, not at whether surgeons like floating data in front of their faces.

The test is simple enough. Watch what happens to Stryker's revenue growth rate after the $5 billion in acquisitions stop showing up as full-year comparisons. If the organic growth holds above the low-teens with stable margins, the premium has a foundation. If it reverts to the mid-single digits, like most large medical device companies eventually do, the stock has a long walk back to a normal multiple. The headset will not change either outcome.